Latest Euronext Brussels News

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at

09/23/2018 02:32 AM

Proximus: A 7.5% Dividend Yield, Thanks To A Greedy Government
Seeking Alpha
Proximus is part of the BEL 20 index on Euronext Brussels, and that's by far the best trading place in terms of liquidity. The average daily volume in Brussels (ticker symbol PROX) is in excess of half a million shares per day, representing in excess ...

09/22/2018 04:25 PM

argenx announces closing of US public offering for gross proceeds of approximately $300.6 million
In addition, argenx announced today the listing of and the commencement of dealings in its 3,475,000 new ordinary shares underlying the ADSs (the New Ordinary Shares) on the regulated market of Euronext Brussels, effective today, September 21, 2018, ...

and more »

09/21/2018 09:02 PM

Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic ...
BioSpace (press release) (blog)
Leuven, Belgium, 20 September 2018 – Oxurion NV (Euronext Brussels: OXUR), a biopharma company (formerly known as ThromboGenics) focused on developing treatments for back of the eye diseases with an innovative pipeline in diabetic eye disease, ...

09/21/2018 08:21 AM

Public Storage Affiliate Shurgard Self Storage Announces Intention to Launch Initial Global Offering
Inside Self-Storage
Update 9/20/18 – Shurgard has announced its intention to launch an initial global offering, which will consist of a private placement on new shares to institutional investors. The company plans to use the proceeds to help fund its growth strategy and ...

09/20/2018 05:40 PM

Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist ...
Leuven, Belgium, 20 September 2018- Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, ...

and more »

09/20/2018 04:40 PM